Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > For Notable. From "Science" 9Dec 21
View:
Post by askretka on Feb 14, 2022 11:39pm

For Notable. From "Science" 9Dec 21

https://www.science.org/doi/10.1126/science.abk3436 Its the abstract only from well known Oncology virus researcher Alan Melcher. It's the Abstract only but I found this part very interesting. ------------------------------------------ (1). This view has now been largely replaced by a model in which infection of the tumor by the virus makes it more visible to the immune system for recognition and attack. Tumor cell killing by the virus and/or immune effector cells EFFECTIVELY GENERATE AN IN SITU VACCINE, with tumor antigens released into a microenvironment modified by viral infection to reverse tumor-induced immune suppression. -------------------------------------------------------- Cheers!!!
Comment by Noteable on Feb 15, 2022 1:03pm
The "new" model of oncoloytic virus therapy is one that ONCY has been demonstrating in the application of pelareorep and its ability to stimulate the innate and adaptive immune system with the effect of overcoming an otherwise immunosuppressive tumor microenvironment (TME) in advance of the addition of checkpoint inhibitor therapy  Independent studies have recently shown that ...more  
Comment by Noteable on Feb 15, 2022 1:56pm
February 14, 2022 -   Harnessing the Immune System to Treat Cancers - [Cancer Research] Combining virotherapy with checkpoint inhibitors "The field is now looking more closely at combining therapeutics, for example administering immunotherapy and virotherapy in different combinations and orders. Using the strengths of each to help each other." https://www.technologynetworks ...more  
Comment by askretka on Feb 16, 2022 7:17pm
Thanks for the Feb 14 link.   https://www.technologynetworks.com/cancer-research/articles/harnessing-the-immune-system-to-treat-cancer-358080 ----------------- "But the downside to this approach is that “for about 80% of cancers, you can't find them, you don't know where they are, they're not amenable to a needle. Therefore, intratumoral delivery doesn't work for ...more  
Comment by askretka on Feb 16, 2022 12:29pm
Thanks Notable. Things seem a bit too for me on the CAR-T front, but after the recent news on CAR-T 10 year survival rate and Novartis possibly with an in Vivo CAR-T in the works, timing for a CAR-T/Pela deal couldn't be better in my opinion. Cheers!!!!